Do SERMs Favorably Impact Clinical Markers of Cardiovascular Risk? In women, menopause is accompanied by clear changes in serum lipoproteins, [30] and plasma lipoprotein levels are clear predictors of ...
Selective estrogen-receptor (ER) modulators (SERMs) are synthetic nonsteroidal compounds that switch on and switch off target sites throughout the body. Tamoxifen, the pioneering SERM, blocks estrogen ...
S-Phase Fraction and Urokinase Plasminogen Activator Are Better Markers for Distant Recurrences Than Nottingham Prognostic Index and Histologic Grade in a Prospective Study of Premenopausal Lymph Node ...
SAN DIEGO and GAINESVILLE, Ga., May 23, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (SCTL) (“Societal CDMO”; Nasdaq: SCTL), a contract development and manufacturing organization (CDMO) dedicated to ...
Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...
The Women’s Health Initiative study in 2002 had a lasting negative effect on the use of menopausal hormone therapy (MHT), which combines estrogen with medroxyprogesterone acetate (MPA). Although the ...
A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor ...
(RTTNews) - Athira Pharma, Inc. (ATHA) has acquired exclusive global rights to Lasofoxifene, a selective estrogen receptor modulator now in pivotal Phase 3 trial for ESR1-mutant metastatic breast ...
Novel lasofoxifene combined with abemaciclib (Verzenio) produced encouraging progression-free survival (PFS) along with acceptable toxicity in pretreated, locally advanced or metastatic breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results